Breast Expansion: The Medical Procedure and Risks

Breast expansion in a medical context refers to the controlled stretching of skin and soft tissue, most commonly using an inflatable device called a tissue expander that is placed beneath the skin and gradually filled with saline over weeks to months. The procedure is overwhelmingly used in breast reconstruction after mastectomy, though it also plays a role in cosmetic augmentation revisions and congenital breast asymmetry correction. Like any surgery involving implanted devices, it carries a layered set of risks that range from common and manageable, like fluid buildup, to rare and serious, like a form of lymphoma linked to certain implant surfaces.

How Tissue Expansion Works

The basic idea behind tissue expansion is surprisingly simple: human skin, when placed under continuous gentle pressure, responds by growing. A silicone balloon is surgically placed beneath the skin and chest muscle, then progressively filled with saline over a series of office visits. Each fill stretches the overlying tissue a little more, creating a pocket large enough to eventually hold a permanent breast implant. This two-stage approach has been a mainstay of breast reconstruction for decades.¹

During the first stage, the surgeon creates what is called a musculofascial pocket and places the expander, sometimes performing additional steps like releasing tight tissue along the breast fold to allow room for the device to sit naturally. The second stage, typically months later, involves removing the expander and swapping it for a permanent implant. At this point, the surgeon selects the final implant size, sets the position of the breast fold, and refines the breast shape.²

There is also a newer category of expanders that use carbon dioxide cartridges instead of saline, allowing patients to self-inflate the device at home with a remote control rather than returning to a clinic for needle fills. A clinical trial comparing the two approaches found that carbon dioxide expanders reached full expansion in a median of 21 days versus 46 days for saline, and the permanent implant exchange surgery happened roughly a month earlier, with similar complication rates between the two groups.³

What Happens Inside the Tissue

Expansion is not just mechanical stretching. The tissue actively remodels in response to the sustained pressure. Animal studies show that expanded skin develops more fibroblasts (the cells that build connective tissue), denser collagen bundles, and increased blood vessel formation compared to unexpanded skin.⁴ Research also indicates that expansion stimulates the growth of skin cells in the deepest layer of the epidermis and promotes new blood vessel development, with bone marrow-derived stem cells contributing to the regeneration process.⁵

This biological remodeling is actually what makes the technique work so well. The extra tissue generated is not just stretched thin like a rubber balloon. It is genuinely new, living tissue with its own blood supply. That said, there are limits. If the expander is filled too fast or too full, the blood supply to the overlying skin can be compromised, which is where some of the most serious short-term complications come from.

Seroma and Infection

The most common complication after tissue expander placement is seroma, a collection of fluid that accumulates in the surgical pocket. Reported rates vary widely, and estimates range from under 1% to 20% of cases depending on the study and how strictly seroma is defined.⁶ One study tracking over 200 reconstructions found that about 13% developed seroma, with aspiration through the expander’s port being the most common treatment.⁷

A seroma on its own is usually not dangerous, but it is not trivial either. Fluid collections raise the risk of infection, and infection near an implanted device can cascade into something much more consequential. That same study found that patients who had any fluid-related concern, whether seroma or prolonged drainage, were significantly more likely to develop an infection and ultimately need the expander removed entirely.⁷ When seroma and infection combine, some data suggest the risk of losing the implant altogether rises by four to six times compared to an uncomplicated case.⁶

Skin Necrosis and the Fill Volume Problem

One of the trickier judgment calls during tissue expansion is how much saline to put into the expander during the initial surgery. Filling it more at the outset means fewer office visits later, but overfilling comes with a steep cost. A study of over 250 breast reconstructions found that when the initial fill volume exceeded 300 cubic centimeters, the odds of the overlying skin dying (mastectomy skin necrosis) jumped roughly tenfold. Above 400 cubic centimeters, the odds rose to about fifteen times higher than conservative fills.⁸

The mechanism is straightforward. A tissue expander, as it fills, presses against the overlying skin from below. That pressure compresses blood vessels, reducing oxygen delivery to the skin flap. Monitoring studies have demonstrated that oxygen supply to the skin can stop entirely at relatively modest expander pressures, well before the skin looks visibly distressed. The clinical takeaway is that more conservative initial fills, with gradual increases over time, give the tissue a chance to develop new blood supply and tolerate the stretching.⁹

When complications like pain, excessive pressure, or early signs of skin damage do arise during the expansion process, the surgeon can draw saline back out through the expander’s self-sealing port. This reversibility is one of the real advantages of the tissue expander approach over some alternatives.¹

Capsular Contracture

Any time the body encounters a foreign object, it builds a shell of scar tissue around it. With breast implants, this shell is called a capsule, and its formation is normal and expected. The problem arises when that capsule tightens and squeezes the implant, a condition called capsular contracture. It can make the breast feel hard, look distorted, and cause chronic discomfort.

The biology behind capsular contracture involves several overlapping processes. Prolonged inflammation around the implant leads to increased activity of specialized cells called myofibroblasts, which have the ability to contract. When collagen fibers in the capsule align in a parallel pattern, these cells can exert enough coordinated force to compress the implant. Bacterial biofilm on the implant surface may also play a role by sustaining a low-grade inflammatory response that drives ongoing scar tissue formation.¹⁰

One innovation aimed at reducing capsular contracture and improving implant stability is the use of acellular dermal matrices, which are processed tissue grafts that provide a scaffold between the implant and the chest wall. These have become a standard component of many implant-based reconstructions, offering better soft tissue coverage and support with generally low complication rates.¹¹

Deflation, Rupture, and Long-Term Implant Failure

Breast implants and tissue expanders are not lifetime devices. Over time, the silicone shell can weaken and eventually fail. Deflation and rupture rates climb with implant age, reaching roughly 15% between three and ten years after implantation. Detecting a rupture is not always straightforward. Not every case produces an obvious change in breast size or shape, and standard mammography does not reliably catch ruptures. MRI is the most accurate tool for identifying implant failure, with a sensitivity of about 87% and specificity around 89%.¹²

For saline-filled expanders and implants, deflation tends to be obvious because the saline leaks out and the breast visibly flattens. Silicone gel implant ruptures are subtler because the gel often stays contained within the surrounding scar capsule, producing what surgeons call a “silent rupture.” This is why the FDA has historically recommended periodic MRI screening for women with silicone gel implants, though adherence to that recommendation is low in practice.

Breast Implant-Associated Lymphoma

Perhaps the most alarming risk to emerge in recent years is breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL. This is a rare T-cell lymphoma that can develop years after placement of a textured breast implant or tissue expander.¹³ By early 2018, over 500 confirmed cases had been documented worldwide.¹⁴

The risk, while real, is very small in absolute terms: estimates put it at roughly 0.35 to 1 case per million persons with breast implants per year.¹⁴ In about 80% of cases, BIA-ALCL first shows up as a late-developing fluid collection around the implant, sometimes years or more than a decade after the original surgery. The average time from implant placement to diagnosis has ranged from 7 to 13 years across studies. In a long-term follow-up of over 3,500 women with textured implants, 10 developed BIA-ALCL after a median exposure of nearly 12 years, and all 10 had macro-textured implants specifically.¹⁵

When caught early, which most cases are, BIA-ALCL is highly treatable. The majority of patients present at a low stage and are treated with implant removal and complete capsulectomy. The association with textured surfaces specifically has led several countries to restrict or ban certain types of macro-textured implants, while smooth-surfaced implants have not been linked to the condition.

Breast Implant Illness

Separate from BIA-ALCL is a cluster of systemic symptoms that some women report developing after receiving breast implants, commonly called breast implant illness. The condition remains medically controversial because the symptoms are nonspecific and overlap with many other conditions. Common complaints include fatigue, joint and muscle pain, difficulty concentrating, rashes, dry eyes, and hair loss.¹⁶

A large systematic review pooling data from over 6,000 women found that symptoms typically appeared about six years after implantation. Fatigue was the most common symptom, reported by about 58% of affected patients, followed by joint pain in about half and muscle pain in roughly 44%. Most women in these studies eventually sought implant removal, with the average time to explantation being about 12 years after the original surgery. Encouragingly, about 82% of patients reported symptom improvement after having their implants removed.¹⁷

The difficulty is that without a clear biomarker or diagnostic test, it is hard to separate true implant-related illness from coincidental symptoms or a placebo-like improvement after removal. The research community has not reached consensus on a pathological mechanism, though some hypotheses involve chronic low-grade immune activation in response to the implant’s silicone shell. For women experiencing these symptoms, explantation with capsulectomy has shown meaningful improvement in many cases, though complete resolution is not guaranteed.¹⁸

When Radiation Is Part of the Picture

For many breast cancer patients, radiation therapy follows mastectomy. The timing of that radiation relative to the tissue expansion process matters enormously. A study comparing outcomes found that patients who received radiation while the tissue expander was still in place had an overall complication rate of about 33%, compared to roughly 11% in those irradiated after the permanent implant exchange. Skin necrosis, wound breakdown, infection, and ultimately the need to remove the device altogether were all significantly higher in the expander-in-place group. The rate of device loss was four times higher: about 16% versus 4%.¹⁹

Radiation damages the small blood vessels that supply the overlying skin, and tissue that is already under mechanical stress from an expander tolerates that damage poorly. This is why surgical teams increasingly coordinate with radiation oncologists about the sequence and timing, though the optimal approach depends on the individual patient’s cancer treatment plan and cannot always be manipulated freely.

Implants and Cancer Screening

Breast implants can interfere with mammography. The implant itself is radiopaque, meaning it shows up as a bright white mass on the image and can obscure breast tissue behind it. Special techniques exist to push the implant out of the way and compress the native breast tissue, but they do not fully eliminate the problem. Research has found that women with implants are more likely to have false-negative mammograms and to present with palpable lumps rather than screen-detected cancers. However, once cancer is diagnosed, there does not appear to be a significant difference in tumor size, recurrence, or survival between augmented and non-augmented women.²⁰

Some researchers have suggested that standard mammographic screening may not be sufficient for women with implants. Ultrasound is considered a useful supplemental tool because it does not involve compression that could damage the implant, and MRI can be added for high-risk patients to improve detection rates.²¹ The practical implication is that if you have breast implants, you should tell your imaging center so they can use modified techniques and potentially recommend supplemental imaging beyond standard mammography.

External Expansion Without Surgery

There is a category of breast expansion that does not involve surgery at all. External volume expansion devices use sustained suction applied through dome-shaped cups worn over the breasts for hours at a time. The sustained negative pressure encourages cell growth, fat tissue development, and new blood vessel formation in the treated area.²²

A clinical trial in Asian women evaluating two external expansion devices found that after 12 weeks of use, breast volume increased by an average of roughly 80 to 100 cubic centimeters, and the number of blood vessels in the breast tissue increased significantly. The devices did not change breast density on imaging.²³ In practical terms, an 80 to 100 cc increase is modest, roughly equivalent to half a cup size or less. External expansion is more commonly used as a preparatory step before fat grafting procedures rather than as a standalone enlargement method, because the improved blood supply in pre-expanded tissue helps transplanted fat cells survive better.

Psychological Outcomes and Satisfaction

For women undergoing breast reconstruction after cancer, the emotional dimension of expansion and implant surgery is significant. Research on body image across different reconstruction stages has found that patients who underwent delayed reconstruction (starting the process after a gap following mastectomy) showed greater improvement in body image dissatisfaction over time compared to those who had immediate reconstruction, possibly because the contrast with living flat-chested was more stark. Starting reconstruction was also associated with higher emotional well-being, regardless of timing.²⁴

Satisfaction scores after expander-implant reconstruction are generally good. One study found that women who completed the process reported good quality of life, low distress, and low decisional regret scores, even among those who subsequently underwent radiation therapy.²⁵ That said, when compared head-to-head with reconstruction using the patient’s own tissue from the abdomen, the implant-based approach consistently scores lower on measures of psychosocial well-being, sexual well-being, and overall satisfaction.²⁶ The trade-off is that tissue-based reconstruction is a much bigger operation with its own set of risks, longer recovery, and donor site morbidity. Most patients choose the expander-implant route because it is less invasive and has a shorter initial recovery, even if the long-term satisfaction ceiling is somewhat lower.

What Explantation Involves

When implants need to come out, whether because of complications, illness symptoms, or simply personal choice, the surgery is not just the reverse of putting them in. Most surgeons recommend removing the scar capsule along with the implant, a procedure called capsulectomy. In one surgical series, a total capsulectomy (removing the entire capsule) was performed in about 62% of cases, with partial removal in the rest. The removed capsule tissue is routinely sent for pathology testing and culture to check for signs of lymphoma or infection.²⁷

After explantation, the breast typically looks deflated because the expanded skin pocket no longer has anything to fill it. Many women opt for a breast lift (mastopexy) at the same time or shortly after to reshape the remaining tissue. Some newer surgical techniques aim to redistribute the existing breast and capsule tissue to preserve volume and shape without adding a new implant. For women who had implants for breast implant illness symptoms specifically, explantation with capsulectomy produced significant improvement in some patient populations, though not all achieved complete resolution, and some required additional treatment.¹⁸